Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA; Department of Pathology, China Medical University, 77 Puhe Rd., Shenbei Xinqu, Shenyang Shi, Liaoning Sheng 110122, China.
Cell Rep. 2018 Jan 9;22(2):350-358. doi: 10.1016/j.celrep.2017.12.055.
Canonical NF-κB signaling is constitutively activated in acute myeloid leukemia (AML) stem cells and is required for maintenance of the self-renewal of leukemia stem cells (LSCs). However, any potential role for NF-κB non-canonical signaling in AML has been largely overlooked. Here, we report that stabilization of NF-κB-inducing kinase (NIK) suppresses AML. Mechanistically, stabilization of NIK activates NF-κB non-canonical signaling and represses NF-κB canonical signaling. In addition, stabilization of NIK-induced activation of NF-κB non-canonical signaling upregulates Dnmt3a and downregulates Mef2c, which suppresses and promotes AML development, respectively. Importantly, by querying the connectivity MAP using up- and downregulated genes that are present exclusively in NIK-stabilized LSCs, we discovered that verteporfin has anti-AML effects, suggesting that repurposing verteporfin to target myeloid leukemia is worth testing clinically. Our data provide a scientific rationale for developing small molecules to stabilize NIK specifically in myeloid leukemias as an attractive therapeutic option.
经典 NF-κB 信号通路在急性髓系白血病(AML)干细胞中持续激活,并且对于维持白血病干细胞(LSCs)的自我更新是必需的。然而,NF-κB 非经典信号通路在 AML 中的任何潜在作用在很大程度上被忽视了。在这里,我们报告 NF-κB 诱导激酶(NIK)的稳定化可以抑制 AML。从机制上讲,NIK 的稳定化激活了 NF-κB 非经典信号通路并抑制了 NF-κB 经典信号通路。此外,NIK 诱导的 NF-κB 非经典信号通路的激活稳定化上调了 Dnmt3a 并下调了 Mef2c,分别抑制和促进 AML 的发展。重要的是,通过查询仅存在于 NIK 稳定化 LSCs 中的上调和下调基因的连通性 MAP,我们发现维替泊芬具有抗 AML 作用,这表明重新利用维替泊芬来靶向髓系白血病在临床上值得测试。我们的数据为开发专门针对髓系白血病的稳定化 NIK 的小分子提供了科学依据,这是一种有吸引力的治疗选择。